BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 28, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» First-in-class CD38 inhibitor shows excellent efficacy in mouse model of mitochondrial myopathy
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Musculoskeletal
First-in-class CD38 inhibitor shows excellent efficacy in mouse model of mitochondrial myopathy
Oct. 10, 2023
No Comments
Researchers from Immunophage Biomedical Co. Ltd. have published details on the discovery and preclinical evaluation of a new CD38 inhibitor being developed for the treatment of mitochondrial myopathy.
BioWorld Science
Musculoskeletal
